为什么人体放射性标记质量平衡研究在临床药理学和药物开发中非常重要？
Human mass-balance studies are also called “C-14 studies” or “Absorption, Metabolism, and Excretion (AME) studies.”…
Certara2022 年 8 月 5 日
Mind-blowing applications of QSP in drug development: Part 1
R&D World editors, Paul Heney and Aimee Kalnoskas, have their minds blown — multiple times!…
Certara2022 年 8 月 4 日
How Pharmaceutical Companies Can Engage Payers Digitally
Pharmaceutical companies should seize opportunities to digitally engage with payers globally using both face-to-face and…
Certara2022 年 7 月 29 日
How the Simcyp Discovery Simulator will Accelerate Early Drug Development
Physiologically-based pharmacokinetic (PBPK) modeling is a technique used to predict the absorption, distribution, metabolism, and…
Certara2022 年 7 月 19 日
Simcyp Discovery Simulator
Tailored for discovery and translational scientists, Simcyp Discovery Simulator is an intuitive software that delivers…
Certara2022 年 7 月 14 日
Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022
PRINCETON, N.J.— 2022 年 7 月 12 日-- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, today…
Certara2022 年 7 月 12 日
Highlights from the FDA-ASCO Workshop on Dose Optimization for Oncology Drugs
The FDA-ASCO (American Society of Clinical Oncology) workshop on oncology dose optimization (3-5 May 2022)…
Certara2022 年 7 月 8 日
Using Clinical Pharmacology & Pharmacometrics to Accelerate Cell Therapy Development: A Patient’s CAR-T Journey
Cell therapies aim to treat, prevent, or potentially cure diseases. They are a relatively new…
Certara2022 年 7 月 8 日
Why FDA’s New Guidance on Circulating Tumor DNA is Critical for Oncology Early Clinical Drug Development
2022 is shaping up to be the “year of the guidance” as the FDA has…
Certara2022 年 7 月 1 日
